- Q1 2024 Zymeworks Inc Earnings Call TranscriptMay 02, 2024$9 (+2.74%)Earnings
- Q4 2023 Zymeworks Inc Earnings Call TranscriptMar 06, 2024$12.23 (+2.09%)Earnings
- Zymeworks Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 22, 2024
- Zymeworks Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Zymeworks Inc Earnings Call TranscriptNov 07, 2023$7.37 (+1.24%)Earnings
- Zymeworks Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Zymeworks Inc at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 Zymeworks Inc Earnings Call TranscriptAug 10, 2023$7.76 (+0.78%)Earnings
- Zymeworks Inc at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Q1 2023 Zymeworks Inc Earnings Call TranscriptMay 08, 2023$8.76 (+1.39%)Earnings
- Zymeworks Inc Investor Call TranscriptApr 18, 2023
- Zymeworks Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Zymeworks Inc Earnings Call TranscriptMar 07, 2023$7.96 (+0.13%)Earnings
- Zymeworks Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Zymeworks Inc HERIZON-BTC-01 Top-Line Results Call TranscriptDec 19, 2022
Zymeworks Inc at Citi BioPharma Conference Transcript
Great. The next panel is ADC antibody drug conjugates. I'm Yigal Nochomovitz. I'm one of the biotech analysts here. I cover all 3 of these companies, MacroGenics, Zai Lab and Zymeworks. So Scott Koenig, CEO of MacroGenics, welcome; Rafael Amado, President, Head of Global Oncology and R&D at Zai Lab; and Paul Moore, CSO at Zymeworks. So thank you all very much for being here. I appreciate it.
Just to start out, why don't we just do a quick lightning around. Give us a very quick introduction to the company and then with a specific focus on your ADC programs and just some of the very key highlights and then we can go from there.
Terrific. Scott Koenig. So MacroGenics is 23 years in operation. We've been focused on developing immune-based therapeutics from the inception. We have 3 validated proprietary platforms, Fc-engineered molecules, bispecifics, which we call DART molecules and then ADC program. The company has been
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)